Form 4: Inmune Bio CEO Raymond Joseph Tesi Acquires Options

Raymond Joseph Tesi, CEO of Inmune Bio, Inc., reports the acquisition of options to purchase 37,882 shares of common stock.

Summary

• On June 10, 2024, Raymond Joseph Tesi, the President and CEO of Inmune Bio, Inc., acquired options to purchase 37,882 shares of the company's common stock.
• The options were granted pursuant to the INmune Bio Inc. 2021 Stock Incentive Plan.
• The exercise price of the options is $8.72 per share.
• The options are fully vested and exercisable as of the grant date, with an expiration date of June 9, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. It doesn't inherently indicate positive or negative performance, but rather a standard compensation practice.

Positives

• The CEO's acquisition of options may signal confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Key Dates